Axplora, a global leader in API small molecule manufacturing, has announced a €6.5 million investment to expand production capacity at its Vizag site in India. This move aims to boost output and strengthen the company’s supply chain resilience amid growing global demand for pharmaceutical ingredients.
The investment comes on the heels of successful 2025 US Food and Drug Administration (USFDA) inspections at both Axplora’s Vizag and Chennai manufacturing sites, which operate under the company’s PharmaZell Business Unit. Both facilities received a Voluntary Action Indicated (VAI) classification, affirming their compliance with international regulatory standards.
The Chennai site was notably praised for its strong implementation of current Good Manufacturing Practices (cGMP), efficient document management, and high standards of facility upkeep and hygiene.
Martin Meeson, CEO of Axplora, stated, “This investment reflects Axplora’s strategic commitment to operational excellence and customer-centric growth. By strengthening our infrastructure in Vizag, we are enhancing our ability to deliver high-quality, reliable, and scalable solutions to customers worldwide.”
Anant Barbadikar, Co-President of PharmaZell and COO India, added, “The success of both inspections highlights not just regulatory compliance, but the operational integrity and continuous improvement culture we embed across every Axplora site.”
The expansion at Vizag will also support the company’s sustainability goals by promoting efficient, vertically integrated production within a single facility, while creating new jobs locally.
With this investment and proven regulatory excellence, Axplora reaffirms its long-term commitment to India as a key strategic hub and a trusted partner to the global pharmaceutical industry.